Boceprevir meets HCV endpoints

Merck & Co. Inc. (NYSE:MRK) said two Phase III trials of boceprevir to treat HCV met their primary endpoints. In both trials, the HCV NS3/4A protease inhibitor plus PegIntron peginterferon alfa-2b and...